L
LAM Therapeutics
Drugs for rare diseases and cancer
About LAM Therapeutics
LAM Therapeutics is a clinical-stage drug development company that focuses on creating precision therapeutics and companion diagnostics for cancer and rare diseases. The company's approach is to match drugs to the specific genetic makeup of a patient's tumor, a strategy that can lead to more effective treatments.
LAM Therapeutics utilizes a technology platform that includes next-generation sequencing and computational biology to analyze the genetic drivers of a patient's disease. This allows the company to identify the most appropriate drug candidate and to develop a companion diagnostic test to select patients who are most likely to respond to the treatment. The company's business model is centered on developing a pipeline of targeted therapies and then partnering with larger pharmaceutical companies for late-stage development and commercialization.
By focusing on genetically-defined patient populations, LAM Therapeutics aims to reduce the time and cost of drug development and to increase the probability of success. The company's primary clients are patients with cancer and rare diseases, and it operates in the biotechnology and pharmaceutical markets.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Guilford, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 67.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, DT and LS
- Technology
- Big Data, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Mar 2017 | $58M | $232M | Yuansheng BioVenture | — |
| LATE VCOther financing | Feb 2016 | $40M | $160M | Undisclosed | — |
Growth signals
Latest recorded traffic for LAM Therapeutics is 240 monthly website visits. LAM Therapeutics's team declined 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Yuansheng BioVenture
Other known investors1 additional known investor
Yale University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about LAM Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LAM Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.